RhumbLine Advisers
BIOR

RhumbLine Advisers’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

RhumbLine Advisers’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$10 – 4416
2024
Q2 		$10 Hold
2
– – ﹤0.01% 4363
2024
Q1 		$18 Hold
2
– – ﹤0.01% 4246
2023
Q4 		$23 Hold
2
– – ﹤0.01% 4264
2023
Q3 		$37 Hold
2
– – ﹤0.01% 4294
2023
Q2 		$67 Buy
+2
New +$71 ﹤0.01% 4371

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

RhumbLine Advisers's BIOR Position: Q3 2024 in Review

RhumbLine Advisers sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q3 2024, closing a stake of 2 shares — an estimated $10 sold.

RhumbLine Advisers first reported a position in BIOR in Q2 2023 and held it in 5 quarters. The position peaked at $67 in Q2 2023. 20 funds tracked by Wall St. Rank hold BIOR as of Q3 2024.

  • RhumbLine Advisers reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 2 Biora Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $10.
  • RhumbLine Advisers first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2023 and held it in 5 quarters.
  • RhumbLine Advisers's Biora Therapeutics, Inc. Common Stock position peaked at $67 in Q2 2023.
  • 20 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.